We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase 4 IOP Signals Associated With ILUVIEN® (PALADIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02424019
Recruitment Status : Completed
First Posted : April 22, 2015
Last Update Posted : January 11, 2022
Information provided by (Responsible Party):
Alimera Sciences

Brief Summary:
This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.

Condition or disease Intervention/treatment Phase
Diabetic Macular Edema (DME) Drug: ILUVIEN 0.19 MG Phase 4

Detailed Description:
The specific objectives include the study of intraocular pressure (IOP) related data in patients who received ILUVIEN and how it relates to the patient's experiences following prior treatment with a course of corticosteroid which did not result in a clinically significant IOP elevation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 153 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg
Actual Study Start Date : May 6, 2015
Actual Primary Completion Date : July 29, 2020
Actual Study Completion Date : July 31, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ILUVIEN 0.19 MG
All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
Drug: ILUVIEN 0.19 MG
Other Name: Fluocinolone Acetonide Intravitreal Implant 0.19 mg

Primary Outcome Measures :
  1. Intraocular Pressure [ Time Frame: 36 months ]
    Intraocular pressure of the ILUVIEN treated eye

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who are eligible for treatment with ILUVIEN based on the Prescribing Information.

Exclusion Criteria:

  • Patients who are unable to understand and sign the Informed Consent Form.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02424019

Show Show 41 study locations
Sponsors and Collaborators
Alimera Sciences
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alimera Sciences
ClinicalTrials.gov Identifier: NCT02424019    
Other Study ID Numbers: M-01-15-004
First Posted: April 22, 2015    Key Record Dates
Last Update Posted: January 11, 2022
Last Verified: January 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Edema
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Fluocinolone Acetonide
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs